Q BioMed Inc. (OTCQB:QBIO) has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to the nuclear medicine, radioisotope research, pharmaceutical, and medical device industries.
Under the terms of the agreement, Q BioMed said isoSolutions has received the exclusive rights to distribute Strontium89 in Canada.
Strontium89, approved by the US Food and Drug Administration (FDA), is a non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor. Common primary tumors that metastasize to the bone include prostate, breast, and lung, as well as others.
READ: Q BioMed inks license deal with Clionix for sales of Strontium89 in Europe and the Middle East
In the Strontium89 pivotal trial, the company noted, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for three months compared with placebo. Furthermore, new pain sites were less frequent in patients treated with Strontium89.
Over 10 million people around the world suffer from pain associated with metastatic cancer in the bone and Q BioMed said they may benefit from Strontium89. For nearly two years, there has been little to no access to this vital therapy.
Q BioMed said it and isoSolutions will work together to increase the awareness of doctors and patients to the availability of Strontium89, while Q BioMed actively pursues full regulatory and marketing approval for the drug in Canada, as well as in other markets worldwide.
"With the improvement of cancer treatments, providing treatment options to patients suffering from painful skeletal metastases is becoming more and more important,” said Kristin Keller, Q BioMed’s chief commercial officer, in a statement. “We are happy to collaborate with isoSolutions and provide patients in Canada with Strontium89, a viable treatment for patients suffering from painful skeletal metastases caused by cancer."
Arun Singh, isoSolutions Managing Director, added: "For the last few years, we had several requests from doctors in Canada, asking for the availability of Strontium89; we are very happy to collaborate with Q BioMed and bring Strontium89 to patients suffering from painful skeletal metastases caused by cancer to Canada."
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham